AB0742 ULTRASONOGRAPHY OF THE NAIL UNIT IN PSORIASIS AND PSORIATIC ARTHRITIS: A QUALITATIVE AND QUANTITATIVE ANALYSIS
Background: the nail unit is a shared topic of interest both for dermatologist and rheumatologist [1] . It is easy to study using imaging techniques such as ultrasonography. The nail was considered one of the possible target of assessment for the disease, especially when ultrasonography is performed. Ultrasound imaging of nails is a quite new technique, available since high frequencies probes were introduced in musculoskeletal examination and nail was considered one of the possible target for assessing the disease and defining its prognosis [2, 3] . Objectives: to evaluate the presence of the nail involvement and subclinical alterations using ultrasonography in psoriasis and psoriatic arthritis. Methods: the study sample included 82 patients affected by psoriasis and/or psoriatic arthritis and 50 healthy controls (HC). The patients were consecutively enrolled during their routine visit in the outpatient clinic and they performed clinical and ultrasonographic evaluation of the nail. Activity indexes (DAPSA, PASI, NAPSI) and other clinimetric parameters were considered. Results: multivariate analysis of variance (mANOVA) was performed between groups and the nail plate and nail bed thickness, PASI, NAPSI, age and BMI were considered (table 1) . Post hoc analysis underlined the differences between groups, in particular between healthy and affected. The lesions for nail plate and nail bed in the PASI score were analyzed using Pearson's chi square test and, Background: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM 1 and 2) and psoriatic arthritis (PsA; PALACE 1-3). Objectives: We report incidence of MACE, malignancies, and serious infections (SIs; opportunistic and non-opportunistic) in pts receiving APR 30 mg BID (APR30) for ≥156 wks in a pooled analysis of these studies. Methods: Incidence rates and exposure-adjusted incidence rates (EAIR)/100 pt-yrs of MACE, malignancies, SIs, and serious opportunistic infections (SOIs) are reported for 0 to 16 wks, 0 to ≤52 wks, and the APR-exposure period (0 to ≥156 wks) for pts receiving APR30 any time during the studies, through February 2015; ∼30% (n=575) of pts received >3 yrs (>156 wks) of APR exposure. Results: 2,242 pts were included in the safety analysis for 0 to 16 wks (PBO n=913, pt-yrs exposure [py]=260.2; APR30 n=1,329, py=377.8); 1,905 pts received APR30 during the APR-exposure period, representing 3,527.5 py; exposure during 0 to ≤52 wks was 1,524.5 py. At baseline 64.2% of PsA pts (PALACE 1-3) in the APR30 group were receiving concomitant DMARDs (including methotrexate). Incidence of MACE with APR30 was low and comparable to PBO during 0 to 16 wks. During 0 to ≤52 wks and the APR-exposure period, incidence of MACE (EAIR/100 pt-yrs) remained low (Table) . Incidence rates (EAIR/100 pt-yrs) of hematologic malignancies, non-melanoma skin cancers, and solid tumors were similar with PBO (0.0, 1.2, 0.4) and APR30 (0.0, 1.3, 0.3) during 0 to 16 wks; incidence rates remained low during 0 to ≤52 wks and the APR-exposure period (Table) . During 0 to 16 wks, the overall rate of infections (serious and non-serious) was low and comparable between pts receiving PBO (20.6%) and APR30 (24.8%). The overall rate of infections (serious and non-serious) was 42% during 0 to ≤52 wks and comparable to rates during the PBO-controlled period (0 to 16 wks); the majority of reported infections (URTI, nasopharyngitis, sinusitis) were not serious. During the PBO-controlled period (0 to 16 wks), rates of SIs with APR30 were low and comparable to PBO; no SOIs were reported. During 0 to ≤52 wks, the overall rate of SIs was low (0.6%; EAIR/100 pt-yrs: 0.7). The rate of SIs remained low (1.8%; EAIR/100 pt-yrs: 1.0) during the long-term cumulative APR-exposure period (0 to ≥156 wks) ( Table) . No clustering of any particular event was noted with respect to SIs; most events occurred in only 1 pt. No clinical reactivation of tuberculosis was reported with long-term APR30 exposure (0 to ≥156 wks). The rate of marked hematologic abnormalities remained low with long-term APR exposure.
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